Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B (June 1990). "CD44 is the principal cell surface receptor for hyaluronate". Cell. 61 (7): 1303–1313. doi:10.1016/0092-8674(90)90694-a. PMID1694723. S2CID8217636.
Alves CS, Burdick MM, Thomas SN, Pawar P, Konstantopoulos K (April 2008). "The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion". American Journal of Physiology. Cell Physiology. 294 (4): C907 –C916. doi:10.1152/ajpcell.00463.2007. PMID18234849. S2CID31373618.
Sackstein R, Dimitroff CJ (October 2000). "A hematopoietic cell L-selectin ligand that is distinct from PSGL-1 and displays N-glycan-dependent binding activity". Blood. 96 (8): 2765–2774. doi:10.1182/blood.V96.8.2765. PMID11023510.
Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, et al. (February 2008). "Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone". Nature Medicine. 14 (2): 181–187. doi:10.1038/nm1703. PMID18193058. S2CID5095656.
Assimakopoulos D, Kolettas E, Patrikakos G, Evangelou A (October 2002). "The role of CD44 in the development and prognosis of head and neck squamous cell carcinomas". Histology and Histopathology. 17 (4): 1269–1281. doi:10.14670/HH-17.1269. PMID12371152.
Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B (June 1990). "CD44 is the principal cell surface receptor for hyaluronate". Cell. 61 (7): 1303–1313. doi:10.1016/0092-8674(90)90694-A. PMID1694723. S2CID8217636.
Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B (June 1990). "CD44 is the principal cell surface receptor for hyaluronate". Cell. 61 (7): 1303–1313. doi:10.1016/0092-8674(90)90694-a. PMID1694723. S2CID8217636.
Alves CS, Burdick MM, Thomas SN, Pawar P, Konstantopoulos K (April 2008). "The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion". American Journal of Physiology. Cell Physiology. 294 (4): C907 –C916. doi:10.1152/ajpcell.00463.2007. PMID18234849. S2CID31373618.
Sackstein R, Dimitroff CJ (October 2000). "A hematopoietic cell L-selectin ligand that is distinct from PSGL-1 and displays N-glycan-dependent binding activity". Blood. 96 (8): 2765–2774. doi:10.1182/blood.V96.8.2765. PMID11023510.
Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, et al. (February 2008). "Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone". Nature Medicine. 14 (2): 181–187. doi:10.1038/nm1703. PMID18193058. S2CID5095656.
Assimakopoulos D, Kolettas E, Patrikakos G, Evangelou A (October 2002). "The role of CD44 in the development and prognosis of head and neck squamous cell carcinomas". Histology and Histopathology. 17 (4): 1269–1281. doi:10.14670/HH-17.1269. PMID12371152.
Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B (June 1990). "CD44 is the principal cell surface receptor for hyaluronate". Cell. 61 (7): 1303–1313. doi:10.1016/0092-8674(90)90694-A. PMID1694723. S2CID8217636.
Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B (June 1990). "CD44 is the principal cell surface receptor for hyaluronate". Cell. 61 (7): 1303–1313. doi:10.1016/0092-8674(90)90694-a. PMID1694723. S2CID8217636.
Alves CS, Burdick MM, Thomas SN, Pawar P, Konstantopoulos K (April 2008). "The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion". American Journal of Physiology. Cell Physiology. 294 (4): C907 –C916. doi:10.1152/ajpcell.00463.2007. PMID18234849. S2CID31373618.
Sackstein R, Merzaban JS, Cain DW, Dagia NM, Spencer JA, Lin CP, et al. (February 2008). "Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone". Nature Medicine. 14 (2): 181–187. doi:10.1038/nm1703. PMID18193058. S2CID5095656.
Eibl RH, Pietsch T, Moll J, Skroch-Angel P, Heider KH, von Ammon K, et al. (December 1995). "Expression of variant CD44 epitopes in human astrocytic brain tumors". Journal of Neuro-Oncology. 26 (3): 165–170. doi:10.1007/bf01052619. PMID8750182. S2CID21251441.
Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y (November 2002). "CD44 in cancer". Critical Reviews in Clinical Laboratory Sciences. 39 (6): 527–579. doi:10.1080/10408360290795574. PMID12484499. S2CID30019668.
Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B (June 1990). "CD44 is the principal cell surface receptor for hyaluronate". Cell. 61 (7): 1303–1313. doi:10.1016/0092-8674(90)90694-A. PMID1694723. S2CID8217636.